MX2021006714A - Neurotoxinas cationicas. - Google Patents

Neurotoxinas cationicas.

Info

Publication number
MX2021006714A
MX2021006714A MX2021006714A MX2021006714A MX2021006714A MX 2021006714 A MX2021006714 A MX 2021006714A MX 2021006714 A MX2021006714 A MX 2021006714A MX 2021006714 A MX2021006714 A MX 2021006714A MX 2021006714 A MX2021006714 A MX 2021006714A
Authority
MX
Mexico
Prior art keywords
clostridial toxin
amino acid
acid modification
engineered clostridial
neurotoxins
Prior art date
Application number
MX2021006714A
Other languages
English (en)
Inventor
Dina Brady Anderson
Gavin Stephen Hackett
Sai Man Liu
Original Assignee
Ipsen Bioinnovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Bioinnovation Ltd filed Critical Ipsen Bioinnovation Ltd
Publication of MX2021006714A publication Critical patent/MX2021006714A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24068—Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)

Abstract

La presente invención proporciona una toxina clostridial modificada que comprenden al menos una modificación de aminoácido, en donde tal al menos una modificación de aminoácido aumenta el punto isoeléctrico (pI) de la toxina clostridial modificada a un valor que es al menos 0.2 unidades pI más alto que el pI de una toxina clostridial idéntica que por el contrario carece de tal al menos una modificación de aminoácido. También se proveen los usos correspondientes de la toxina clostridial modificada en terapia.
MX2021006714A 2013-07-09 2016-01-07 Neurotoxinas cationicas. MX2021006714A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1312317.9A GB201312317D0 (en) 2013-07-09 2013-07-09 Cationic neurotoxins

Publications (1)

Publication Number Publication Date
MX2021006714A true MX2021006714A (es) 2021-07-15

Family

ID=49033565

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016000047A MX2016000047A (es) 2013-07-09 2014-07-09 Neurotoxinas cationicas.
MX2021006714A MX2021006714A (es) 2013-07-09 2016-01-07 Neurotoxinas cationicas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016000047A MX2016000047A (es) 2013-07-09 2014-07-09 Neurotoxinas cationicas.

Country Status (24)

Country Link
US (2) US9920310B2 (es)
EP (2) EP3019190B1 (es)
JP (4) JP6850127B2 (es)
KR (3) KR20240005140A (es)
CN (2) CN105492020B (es)
AR (2) AR096869A1 (es)
AU (1) AU2014288953C1 (es)
CA (1) CA2917009A1 (es)
DK (1) DK3019190T3 (es)
EA (2) EA202191745A1 (es)
ES (1) ES2881301T3 (es)
GB (1) GB201312317D0 (es)
HK (1) HK1222795A1 (es)
HU (1) HUE055733T2 (es)
IL (3) IL243330B (es)
MX (2) MX2016000047A (es)
PL (1) PL3019190T3 (es)
PT (1) PT3019190T (es)
SA (1) SA516370371B1 (es)
SG (2) SG10202005416PA (es)
TW (3) TWI694081B (es)
UA (1) UA126889C2 (es)
WO (1) WO2015004461A1 (es)
ZA (1) ZA201801413B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
CN107109389A (zh) * 2014-08-12 2017-08-29 拜奥麦迪逊公司 具有修饰的轻链特异性的肉毒杆菌神经毒素及其生产方法
US10647750B2 (en) * 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) * 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
GB201607901D0 (en) * 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
FI3481852T3 (fi) * 2016-07-08 2023-03-19 Childrens Medical Center Uusi botulinum-neurotoksiini ja sen johdannaisia
TW201814045A (zh) * 2016-09-16 2018-04-16 英商艾普森生物製藥有限公司 製造雙鏈梭狀芽孢桿菌神經毒素之方法
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202001353D0 (en) 2020-01-31 2020-03-18 Ipsen Biopharm Ltd Treatment of skin conditions
GB202003813D0 (en) 2020-03-16 2020-04-29 Ipsen Biopharm Ltd Treatment of upper facial lines
KR20220154738A (ko) 2020-03-16 2022-11-22 입센 바이오팜 리미티드 사지 경직을 치료하기 위한 변형된 보툴리눔 신경독소
GB202011055D0 (en) 2020-07-17 2020-09-02 Ipsen Bioinnovation Ltd Treatment of post-operative pain
WO2022073360A1 (zh) * 2020-10-10 2022-04-14 广州东盛生物科技有限公司 构建新型冠状病毒疫苗的方法及其应用
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
CA3213914A1 (en) 2021-03-30 2022-10-06 Mikhail KALINICHEV Treatment of pain & inflammatory disorders
WO2022208039A1 (en) 2021-03-30 2022-10-06 Ipsen Biopharm Limited Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders
EP4401759A1 (en) 2021-09-16 2024-07-24 Ipsen Biopharm Limited Modified bont/a for use in the treatment of cervical dystonia
EP4404955A1 (en) 2021-09-23 2024-07-31 Ipsen Biopharm Limited Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject
GB202113602D0 (en) 2021-09-23 2021-11-10 Ipsen Biopharm Ltd Treatment of a disorder affecting an eyelid muscle of a subject
WO2023075060A1 (ko) * 2021-10-25 2023-05-04 비피메드(주) 보툴리눔 유래 펩타이드를 포함하는 통증개선용 조성물
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202206353D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of cervical dystonia
GB202206348D0 (en) 2022-04-29 2022-06-15 Ipsen Biopharm Ltd Treatment of limb spasticity
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
CN115819526A (zh) * 2022-12-02 2023-03-21 海雅美生物技术(珠海)有限公司 一种重组肉毒杆菌神经毒素及其制备方法和应用
CH720444A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Clostridium botulinum serotyp a neurotoxin (bont/a)- sequenzvarianten
CH720447A2 (de) 2023-01-20 2024-07-31 Abbvie Inc Zusammensetzungen von clostridium botulinum neurotoxin serotyp a
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015766A1 (en) 1992-02-10 1993-08-19 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
EP1374886B1 (en) 1993-06-10 2009-09-02 Allergan, Inc. Treatment of neuromuscular disorders and conditions with different botulinum serotype
US5437291A (en) 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
US20040126396A1 (en) 1993-12-28 2004-07-01 Allergan, Inc. Botulinum toxin treatment for strabismus
US5670484A (en) 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
US5714469A (en) 1994-09-01 1998-02-03 Smithkline Beecham Corporation Method of treating sepsis
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
US6063768A (en) 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
CN1241945C (zh) 1998-05-13 2006-02-15 拜欧特康生化技术开发和咨询有限公司 用于抑制肥大细胞脱粒的杂合蛋白质及其用途
EP1346731B1 (en) 1998-07-22 2006-12-06 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
JP2004512004A (ja) * 1999-05-12 2004-04-22 ユナイテッド　ステイツ　アーミー　メディカル　リサーチ　アンド　マテリエル　シーエムディー ボツリヌス神経毒に対する組換えワクチン
US6767544B2 (en) 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
US6358917B1 (en) 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
EP1700918B1 (en) 1999-08-25 2014-01-15 Allergan, Inc. Activatable recombinant neurotoxins
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6265379B1 (en) 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US7838008B2 (en) 1999-12-07 2010-11-23 Allergan, Inc. Methods for treating diverse cancers
US6139845A (en) 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6143306A (en) 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6641820B1 (en) 2000-01-19 2003-11-04 Allergan, Inc. Clostridial toxin derivatives and methods to treat pain
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders
US6464986B1 (en) 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6565870B1 (en) 2000-04-28 2003-05-20 Allergan, Inc. Methods for treating bone tumors
US6306403B1 (en) 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US6423319B1 (en) 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US6827931B1 (en) 2000-10-20 2004-12-07 Allergan, Inc. Method for treating endocrine disorders
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US20040028613A1 (en) 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
US6623742B2 (en) 2001-09-17 2003-09-23 Allergan, Inc. Methods for treating fibromyalgia
US7255866B2 (en) 2001-09-17 2007-08-14 Allergan, Inc. Botulinum toxin therapy for fibromyalgia
US6921538B2 (en) 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
KR20050061541A (ko) 2002-10-15 2005-06-22 알러간, 인코포레이티드 보툴리눔 독소 치과 치료 및 시술
US7238357B2 (en) 2002-11-05 2007-07-03 Allergan, Inc. Methods for treating ulcers and gastroesophageal reflux disease
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US8071550B2 (en) 2003-03-03 2011-12-06 Allergan, Inc. Methods for treating uterine disorders
US6838434B2 (en) 2003-05-02 2005-01-04 Allergan, Inc. Methods for treating sinus headache
US7220422B2 (en) 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US20040253274A1 (en) 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
EP1830872B1 (en) 2004-12-01 2010-11-17 Health Protection Agency Fusion proteins
US9180081B2 (en) * 2005-03-03 2015-11-10 Revance Therapeutics, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
US8052979B2 (en) * 2005-03-15 2011-11-08 Allergan, Inc. Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
WO2008008082A2 (en) 2005-09-19 2008-01-17 Allergan, Inc. Clostridial toxin activatable clostridial toxins
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
CA2657460A1 (en) * 2006-07-11 2008-09-04 Allergan, Inc. Modified clostridial toxins with enhanced translocation capability and enhanced targeting activity
EP2178905B1 (en) * 2007-07-26 2013-11-06 Allergan, Inc. Methods of activiting clostridial toxins
WO2009015840A2 (en) * 2007-07-27 2009-02-05 Merz Pharma Gmbh & Co. Kgaa Polypeptide for targeting of neural cells
WO2009042165A2 (en) * 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
JP2011514308A (ja) * 2007-10-23 2011-05-06 アラーガン、インコーポレイテッド 改変クロストリジウム毒素を用いる泌尿生殖器神経学的障害の治療方法
DK2379104T3 (en) * 2008-12-31 2018-04-30 Revance Therapeutics Inc Injectable botulinum toxin formulations
GB0903006D0 (en) 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
WO2010120766A1 (en) 2009-04-14 2010-10-21 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
JP4900443B2 (ja) 2009-09-30 2012-03-21 大日本印刷株式会社 色素増感型太陽電池
WO2011146704A1 (en) * 2010-05-20 2011-11-24 Allergan, Inc. Degradable clostridial toxins
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
US20120189677A1 (en) 2011-01-20 2012-07-26 Stephen Tonge Formulations
SG11201402131TA (en) 2011-11-09 2014-08-28 Merz Pharma Gmbh & Co Kgaa Neurotoxins exhibiting shortened biological activity
EP3372239B1 (en) * 2012-05-30 2020-11-11 President and Fellows of Harvard College Engineered botulinum neurotoxin
GB201312317D0 (en) * 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
GB201407525D0 (en) * 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins

Also Published As

Publication number Publication date
JP2024054234A (ja) 2024-04-16
KR20210154889A (ko) 2021-12-21
NZ715570A (en) 2021-04-30
SA516370371B1 (ar) 2022-01-19
TW202033539A (zh) 2020-09-16
MX2016000047A (es) 2016-05-31
JP7434263B2 (ja) 2024-02-20
WO2015004461A1 (en) 2015-01-15
TW202304956A (zh) 2023-02-01
PL3019190T3 (pl) 2021-12-06
HUE055733T2 (hu) 2021-12-28
JP2022046597A (ja) 2022-03-23
SG10202005416PA (en) 2020-07-29
PT3019190T (pt) 2021-07-21
CN105492020A (zh) 2016-04-13
EP3019190B1 (en) 2021-05-26
AR096869A1 (es) 2016-02-03
US11034947B2 (en) 2021-06-15
AR118777A2 (es) 2021-10-27
KR20240005140A (ko) 2024-01-11
TWI813291B (zh) 2023-08-21
ES2881301T3 (es) 2021-11-29
GB201312317D0 (en) 2013-08-21
IL243330A0 (en) 2016-03-31
DK3019190T3 (da) 2021-07-26
EA039105B1 (ru) 2021-12-03
US20180298366A1 (en) 2018-10-18
TWI776147B (zh) 2022-09-01
EA202191745A1 (ru) 2022-01-31
TW201542587A (zh) 2015-11-16
IL243330B (en) 2020-01-30
CA2917009A1 (en) 2015-01-15
KR20160029110A (ko) 2016-03-14
JP2016523555A (ja) 2016-08-12
HK1222795A1 (zh) 2017-07-14
UA126889C2 (uk) 2023-02-22
AU2014288953A1 (en) 2016-02-11
TWI694081B (zh) 2020-05-21
EP3943105A2 (en) 2022-01-26
KR102617830B1 (ko) 2023-12-27
SG11201600150UA (en) 2016-02-26
AU2014288953C1 (en) 2019-02-14
EP3943105A3 (en) 2022-05-04
EA201690189A1 (ru) 2016-06-30
CN112961227A (zh) 2021-06-15
IL276915A (en) 2020-10-29
EP3019190A1 (en) 2016-05-18
CN105492020B (zh) 2021-03-12
KR102340476B1 (ko) 2021-12-21
JP6850127B2 (ja) 2021-03-31
US9920310B2 (en) 2018-03-20
JP2019129840A (ja) 2019-08-08
US20160369256A1 (en) 2016-12-22
IL276915B (en) 2021-08-31
JP7360802B2 (ja) 2023-10-13
IL270769A (en) 2020-01-30
IL270769B (en) 2021-03-25
ZA201801413B (en) 2019-07-31
AU2014288953B2 (en) 2018-11-01

Similar Documents

Publication Publication Date Title
MX2021006714A (es) Neurotoxinas cationicas.
CY1121891T1 (el) Τροποποιημενα με γενετικη μηχανικη πολυπεπτιδια της λυασης φαινυλαλανινης-αμμωνιας
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
MX2020010262A (es) Manufactura de neurotoxinas de clostridium botulinum recombinantes.
MX371018B (es) Polipéptidos que tienen actividad de transgalactosilación.
ZA201506093B (en) Methods and pharmaceutical composition for the treatment and the prevention of cardiomyopathy due to energy failure
PH12015501983A1 (en) Peptides and compositions for treatment of joint damage
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
IN2014DE00193A (es)
MY181068A (en) Recombinant microorganism for improved production of fine chemicals
MX2020002544A (es) Sales de glicopirrolato.
MX2019009222A (es) Neurotoxinas recombinantes de clostridium botulinum.
PH12016501094A1 (en) Recombinant microorganism for improved production of fine chemicals
PH12017502215A1 (en) Recombinant microorganism for improve production of fine chemicals
PH12017501678A1 (en) Recombinant microorganism for improved production of finie chemicals
PH12014502763A1 (en) Method for the degradation of keratin and use of the keratin hydrolysate produced
MD20150109A2 (ro) Construcţii proteice mitocondriale şi utilizările acestora
MX2018000337A (es) Microorganismos para la produccion de putrescina u ornitina y procedimiento para la produccion de putrescina u ornitina usando los mismos.
MX2017008908A (es) Proceso para la hidrólisis de queratina empleando proteasas.
MX2018015080A (es) Produccion de neurotoxinas clostridiales activadas.
PH12019501325A1 (en) Methods of producing phytoene
IN2014KN02952A (es)
MY173051A (en) Microorganism having producing ability of quinolinic acid and method for producing quinolinic acid using the microorganism
UA79842U (ru) Способ придания стабильных линейных размеров шерстьсодержащим текстильным материалам